{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:43:32Z","timestamp":1764603812862},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,22]]},"DOI":"10.7759\/cureus.18191","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T15:35:53Z","timestamp":1632324953000},"source":"Crossref","is-referenced-by-count":2,"title":["Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension"],"prefix":"10.7759","author":[{"given":"Asma","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanessa F","family":"Matos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Intriago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keval","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasrin","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heeya","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rifath  I","family":"Nishu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima","family":"Marzban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau G","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, et al.. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019, 53:1801913. 10.1183\/13993003.01913-2018","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber HW","year":"2004","unstructured":"Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004, 351:1655-65. 10.1056\/NEJMra035488","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0075","article-title":"The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries","volume":"139","author":"Frost AE","year":"2011","unstructured":"Frost AE, Badesch DB, Barst RJ, et al.. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011, 139:128-37. 10.1378\/chest.10-0075","journal-title":"Chest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020977300","article-title":"Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review","volume":"11","author":"Leber L","year":"2021","unstructured":"Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021, 11:2045894020977300. 10.1177\/2045894020977300","journal-title":"Pulm Circ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.11909\/j.issn.1671-5411.2017.01.001","article-title":"Epidemiology of pulmonary hypertension in the elderly","volume":"14","author":"\u00d6rem C","year":"2017","unstructured":"\u00d6rem C. Epidemiology of pulmonary hypertension in the elderly. J Geriatr Cardiol. 2017, 14:11-6. 10.11909\/j.issn.1671-5411.2017.01.001","journal-title":"J Geriatr Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00004812","article-title":"Pathways in pulmonary arterial hypertension: the future is here","volume":"21","author":"Sitbon O","year":"2012","unstructured":"Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev. 2012, 21:321-7. 10.1183\/09059180.00004812","journal-title":"Eur Respir Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert M","year":"2019","unstructured":"Humbert M, Guignabert C, Bonnet S, et al.. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019, 53:1801887. 10.1183\/13993003.01887-2018","journal-title":"Eur Respir J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm.2020.02.597","article-title":"Current and emerging therapeutic approaches to pulmonary hypertension","volume":"21","author":"Bisserier M","year":"2020","unstructured":"Bisserier M, Pradhan N, Hadri L. Current and emerging therapeutic approaches to pulmonary hypertension. Rev Cardiovasc Med. 2020, 21:163-79. 10.31083\/j.rcm.2020.02.597","journal-title":"Rev Cardiovasc Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Gali\u00e8 N","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, et al.. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016, 37:67-119. 10.1093\/eurheartj\/ehv317","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza RL","year":"2010","unstructured":"Benza RL, Miller DP, Gomberg-Maitland M, et al.. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010, 122:164-72. 10.1161\/CIRCULATIONAHA.109.898122","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2017.01.038","article-title":"Updated risk score calculator for patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)","volume":"195","author":"Benza RL","year":"2017","unstructured":"Benza RL, Elliott CG, Farber HW, et al.. Updated risk score calculator for patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Am J Respir Crit Care Med. 2017, 195:6899. 10.1016\/j.healun.2017.01.038","journal-title":"Am J Respir Crit Care Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL Risk Score Calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza RL","year":"2019","unstructured":"Benza RL, Gomberg-Maitland M, Elliott CG, et al.. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL Risk Score Calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies. Chest. 2019, 156:323-37. 10.1016\/j.chest.2019.02.004","journal-title":"Chest"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88609","article-title":"Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients","volume":"27","author":"Levine DJ","year":"2021","unstructured":"Levine DJ. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. Am J Manag Care. 2021, 27:S35-41. 10.37765\/ajmc.2021.88609","journal-title":"Am J Manag Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst RJ","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, et al.. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996, 334:296-301. 10.1056\/NEJM199602013340504","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/1817-1737.37832","article-title":"Pulmonary hypertension: past, present and future","volume":"3","author":"Barst RJ","year":"2008","unstructured":"Barst RJ. Pulmonary hypertension: past, present and future. Ann Thorac Med. 2008, 3:1-4. 10.4103\/1817-1737.37832","journal-title":"Ann Thorac Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.08.085","article-title":"General measures and supportive therapy for pulmonary arterial hypertension: updated recommendations from the Cologne Consensus Conference 2018","volume":"272S","author":"Gr\u00fcnig E","year":"2018","unstructured":"Gr\u00fcnig E, Benjamin N, Kr\u00fcger U, et al.. General measures and supportive therapy for pulmonary arterial hypertension: updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018, 272S:30-6. 10.1016\/j.ijcard.2018.08.085","journal-title":"Int J Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the CHEST guideline and expert panel report","volume":"155","author":"Klinger JR","year":"2019","unstructured":"Klinger JR, Elliott CG, Levine DJ, et al.. Predicting survival in patients with pulmonary arterial hypertension: the CHEST guideline and expert panel report. Chest. 2019, 155:565-86. 10.1016\/j.chest.2018.11.030","journal-title":"Chest"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-017-0262-z","article-title":"Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study","volume":"18","author":"Coghlan JG","year":"2018","unstructured":"Coghlan JG, Channick R, Chin K, et al.. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs. 2018, 18:37-47. 10.1007\/s40256-017-0262-z","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref19","unstructured":"Drug approval package. (2001). Accessed. April 30 2021: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/20-444S003_Flolan.cfm."},{"key":"ref20","unstructured":"Epoprostenol. (2005). Accessed. April 20, 2021: https:\/\/go.drugbank.com\/drugs\/DB01240."},{"key":"ref21","unstructured":"I.V. therapy made a little easier. (2021). Accessed. April 20 2021: https:\/\/www.veletri.com\/."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3310\/hta13490","article-title":"Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study","volume":"13","author":"Wong IC","year":"2009","unstructured":"Wong IC, Asherson P, Bilbow A, et al.. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study. Health Technol Assess. 2009, 13:iii-iv, ix-xi, 1-120. 10.3310\/hta13490","journal-title":"Health Technol Assess"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0055-2016","article-title":"Epoprostenol and pulmonary arterial hypertension: 20\u2005years of clinical experience","volume":"26","author":"Sitbon O","year":"2017","unstructured":"Sitbon O, Vonk Noordegraaf A. Epoprostenol and pulmonary arterial hypertension: 20\u2005years of clinical experience. Eur Respir Rev. 2017, 26:10.1183\/16000617.0055-2016","journal-title":"Eur Respir Rev"},{"key":"ref24","article-title":"Inpatient use of inhaled pulmonary vasodilator therapy in patients infected with COVID-19. Expert analysis","author":"Rjpal S","year":"2020","unstructured":"Rjpal S. Inpatient use of inhaled pulmonary vasodilator therapy in patients infected with COVID-19. Expert analysis. American College of Cardiology. 2020,","journal-title":"American College of Cardiology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195195","article-title":"Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)-An open-label, single-arm study","volume":"13","author":"Mihara K","year":"2018","unstructured":"Mihara K, Ogawa A, Matsubara H, Terao T, Ichikawa Y. Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)-An open-label, single-arm study. PLoS One. 2018, 13:e0195195. 10.1371\/journal.pone.0195195","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert M","year":"2004","unstructured":"Humbert M, Barst RJ, Robbins IM, et al.. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004, 24:353-9. 10.1183\/09031936.04.00028404","journal-title":"Eur Respir J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002575","article-title":"Comparative efficacy and safety of prostacyclin analogs for pulmonary arterial hypertension: a network meta-analysis","volume":"95","author":"Zhang H","year":"2016","unstructured":"Zhang H, Li X, Huang J, Li H, Su Z, Wang J. Comparative efficacy and safety of prostacyclin analogs for pulmonary arterial hypertension: a network meta-analysis. Medicine (Baltimore). 2016, 95:e2575. 10.1097\/MD.0000000000002575","journal-title":"Medicine (Baltimore)"},{"key":"ref28","unstructured":"Full prescribing information. (2019). Accessed. May 8, 2021: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Flolan\/pdf\/FLOLAN-PI-PIL.PDF."},{"key":"ref29","unstructured":"Welcome to RxNav. (2006). Accessed. April 30 2021: https:\/\/mor.nlm.nih.gov\/RxNav\/search."},{"key":"ref30","unstructured":"CARIPUL Epoprostenol for injection. (2020). Accessed. April 30, 2021:  https:\/\/pdf.hres.ca\/dpd_pm\/00059324.PDF.."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001713","article-title":"Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?","volume":"22","author":"Seferian A","year":"2013","unstructured":"Seferian A, Simonneau G. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?. Eur Respir Rev. 2013, 22:217-26. 10.1183\/09059180.00001713","journal-title":"Eur Respir Rev"},{"key":"ref32","unstructured":"Epoprostenol dosing information.[Internet]. Drugs. Available. https:\/\/www.drugs.com\/mtm\/epoprostenol.html. Accessed June 04. (2021). https:\/\/www.drugs.com\/mtm\/epoprostenol.html. Accessed June 04, 2021.."},{"key":"ref33","unstructured":"Epoprostenol(Rx). (2020). Accessed. June 04 2021:  https:\/\/reference.medscape.com\/\/drug\/flolan-epoprostenol-342398."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(76)90126-x","article-title":"The chemical structure of prostaglandin X (prostacyclin). Prostaglandins","volume":"12","author":"Whittaker N","year":"1976","unstructured":"Whittaker N, Bunting S, Salmon J, et al.. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins. Science Direct. 1976, 12:915-928. 10.1016\/0090-6980(76)90126-x","journal-title":"Science Direct"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(99)80377-4","article-title":"Pharmacodynamic profile of prostacyclin.","volume":"75","author":"Vane JR","year":"1995","unstructured":"Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. . Am J Cardiol. 1995, 75:3. 10.1016\/s0002-9149(99)80377-4","journal-title":"Am J Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland M","year":"2008","unstructured":"Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008, 31:891-901. 10.1183\/09031936.00097107","journal-title":"Eur Respir J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1067\/mlc.2001.119329","article-title":"Physiologic basis for the treatment of pulmonary hypertension","volume":"138","author":"Olschewski H","year":"2001","unstructured":"Olschewski H, Olschewski A, Rose F, et al.. Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med. 2001, 138:287-97. 10.1067\/mlc.2001.119329","journal-title":"J Lab Clin Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S29916","article-title":"Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted","volume":"6","author":"Lambert O","year":"2012","unstructured":"Lambert O, Bandilla D, Iyer R, Witchey-Lakshmanan L, Palepu N. Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted. Drug Des Devel Ther. 2012, 6:61-70. 10.2147\/DDDT.S29916","journal-title":"Drug Des Devel Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02525.x","article-title":"How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?","volume":"168","author":"Barst R","year":"2010","unstructured":"Barst R. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?. Int J Clin Pract Suppl. 2010, 168:23-32. 10.1111\/j.1742-1241.2010.02525.x","journal-title":"Int J Clin Pract Suppl"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00017809","article-title":"Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease","volume":"34","author":"Montani D","year":"2009","unstructured":"Montani D, Ja\u00efs X, Price LC, et al.. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J. 2009, 34:1348-56. 10.1183\/09031936.00017809","journal-title":"Eur Respir J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(15)61538-8","article-title":"Effect of Selexipag on morbidity\/mortality in pulmonary arterial hypertension: Results of The GRIPHON Study","volume":"65","author":"McLaughlin V. V","year":"2015","unstructured":"McLaughlin V. V, Channick R, Chin K, et al.. Effect of Selexipag on morbidity\/mortality in pulmonary arterial hypertension: Results of The GRIPHON Study. J AM COLL CARDIOL. 2015, 65:A1538. 10.1016\/s0735-1097(15)61538-8","journal-title":"J AM COLL CARDIOL"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.08.007","article-title":"EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension","volume":"167","author":"Sitbon O","year":"2014","unstructured":"Sitbon O, Delcroix M, Bergot E, et al.. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am Heart J. 2014, 167:210-7. 10.1016\/j.ahj.2013.08.007","journal-title":"Am Heart J"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0029-0","article-title":"Evaluation of a new formulation of epoprostenol sodium in Japanese patients with pulmonary arterial hypertension (EPITOME4)","volume":"30","author":"Tamura Y","year":"2013","unstructured":"Tamura Y, Ono T, Fukuda K, Satoh T, Sasayama S. Evaluation of a new formulation of epoprostenol sodium in Japanese patients with pulmonary arterial hypertension (EPITOME4). Adv Ther. 2013, 30:459-71. 10.1007\/s12325-013-0029-0","journal-title":"Adv Ther"},{"key":"ref44","unstructured":"Comparison of vasodilator response of inhaled epoprostenol and inhaled nitric oxide. (2020). Accessed. August 16 2021: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04231084."},{"key":"ref45","unstructured":"PGI2 versus nitroglycerine for management of pulmonary hypertension after valve surgeries. (2020). Accessed. August 16 2021: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04594629.."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/69711-use-of-epoprostenol-in-the-treatment-of-pulmonary-arterial-hypertension","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:59Z","timestamp":1707506999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/69711-use-of-epoprostenol-in-the-treatment-of-pulmonary-arterial-hypertension"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.18191","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,22]]}}}